替吉奥联合奥沙利铂对中晚期胃癌患者预后及血清胃泌素的影响

Effect of S-1 Combined with Oxaliplatin on Prognosis and Serum Gastrin Expression of the Patients with Advanced Gastric Cancer

目的探讨替吉奥联合奥沙利铂对中晚期胃癌患者预后及血清胃泌素(GAS)的影响。方法 50例中晚期胃癌患者接受替吉奥联合奥沙利铂术后化疗,2周期后分别评估患者的和血清GAS表达以及不良反应。结果全组化疗有效率为76. 00%,临床症状部分缓解、疾病稳定及疾病进展患者GAS表达依次升高(P <0. 05)。胃癌患者化疗后骨髓抑制、胃肠道反应、肝肾功能异常及外周神经毒性发生率分别为42. 37%、63. 58%、17. 37%、51. 92%。结论替吉奥联合奥沙利铂治疗中晚期胃癌患者预后较好,血清GAS表达明显下降,对临床治疗具有积极的指导意义。

Objective To investigate the effect of S-1 combined with oxaliplatin on prognosis and serum gastrin （GAS） expression of the patients with advanced gastric cancer. Methods Fifty-patients with advanced gastric cancer received the postoperative chemotherapy with 5-1 combined with oxaliplatin, and the prognosis, serum GAS expression and toxicities were observed after two cycles of chemotherapy. Results The effective rate of chemotherapy was 76.00%, the expression of GAS in patients with partial remission, stable disease or disease progression was increased, there were significant differences in the GAS level among the three groups （ P 〈 0.05 ）. The incidences of myelosuppression, gastrointestinal reaction, abnormal liver or kidney function and peripheral nerve toxicity were 42.37%, 63.58%, 17.37% , 51.92%. Conclusion 5-1 combined with oxaliplatin can improve the prognosis of patients with advanced gastric cancer, and decrease the serum GAS expression.